A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION
Markowitz SN, Devenyi RG, Munk MR, Croissant CL, Tedford SE, Rückert R, Walker MG, Patino BE, Chen L, Nido M, Tedford CE
Retina (Philadelphia, Pa.) · 86 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- National Eye Institute
- Government
- NEI NIH HHS
- Grants
- National Eye Institute (R43 EY025508)
Based on 2 listed funder(s).
Publication
- Published
- 2019-08-11 · Retina · vol. 40 · issue 8 · pp. 1471–1482
- Publisher
- Lippincott Williams & Wilkins
- Cited
- 119 citations · more than 96% of similar papers · 4.8× the field average
- Impact
- Top 10% most cited in its field
- References
- 39 works
- Access
- Open access (hybrid journal) · CC-BY
- Research areas
- Laser Applications in Dentistry and Medicine · Retinal Diseases and Treatments · Ophthalmology and Visual Impairment Studies
- Keywords
- Drusen, Microperimetry, Medicine, Macular degeneration, Ophthalmology, Visual acuity, Adverse effect, Internal medicine
- MeSH
- humans, retinal drusen, treatment outcome, prospective studies, double-blind method, contrast sensitivity, visual acuity, visual fields, quality of life, aged, aged, 80 and over, middle aged, female, male, geographic atrophy, visual field tests, surveys and questionnaires, low-level light therapy
11 authors
From CA, CH, US
- Samuel N. Markowitz · correspondingUniversity of Toronto
- Robert G. Devenyi · correspondingUniversity Health Network; University of Toronto
- Marion Ronit MunkUniversity Hospital of Bern
- Cindy L. CroissantPeninsula Cancer Center
- Stephanie E. TedfordPeninsula Cancer Center
- René Rückert
Abstract
Purpose
The LIGHTSITE I study investigated the efficacy and safety of photobiomodulation (PBM) treatment in subjects with dry age-related macular degeneration.
Methods
Thirty subjects (46 eyes) were treated with the Valeda Light Delivery System, wherein subjects underwent two series of treatments (3× per week for 3-4 weeks) over 1 year. Outcome measures included best-corrected visual acuity, contrast sensitivity, microperimetry, central drusen volume and drusen thickness, and quality of life assessments.
Results
Photobiomodulation-treated subjects showed a best-corrected visual acuity mean letter score gain of 4 letters immediately after each treatment series at Month 1 (M1) and Month 7 (M7). Approximately 50% of PBM-treated subjects showed improvement of ≥5 letters versus 13.6% in sham-treated subjects at M1. High responding subjects (≥5-letter improvement) in the PBM-treated group showed a gain of 8 letters after initial treatment (P < 0.01) and exhibited earlier stages of age-related macular degeneration disease. Statistically significant improvements in contrast sensitivity, central drusen volume, central drusen thickness, and quality of life were observed (P < 0.05). No device-related adverse events were reported.
Conclusion
Photobiomodulation treatment statistically improved clinical and anatomical outcomes with more robust benefits observed in subjects with earlier stages of dry age-related macular degeneration. Repeated PBM treatments are necessary to maintain benefits. These pilot findings support previous reports and suggest the utility of PBM as a safe and effective therapy in subjects with dry age-related macular degeneration.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.